NCT06797609View on ClinicalTrials.gov

Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome

Active, not recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Nephrotic Syndrome
Interventions
OTHER

Sample analyses

Immunoturbidimetric assay for determination of serum Cys-C levels and the Chronic Kidney Disease Epidemiology (CKD-EPI) equation for GFR estimation

Trial Locations (2)

24020

Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Ranica

24027

ASST Papa Giovanni XXIII, Bergamo

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT06797609 - Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome | Biotech Hunter | Biotech Hunter